Destiny Pharma PLC teams up with US Department of Veterans Affairs to find ‘new attributes’ for its next-generation antibiotic
NTCD-M3 is being developed to combat Clostridioides difficile infections (CDI) in the gut () said it is teaming up with...
NTCD-M3 is being developed to combat Clostridioides difficile infections (CDI) in the gut () said it is teaming up with...
